Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies.
[Meso-1,2-bis(2,6-dihalo-3/4-hydroxyphenyl)ethylenediamine]platinum(II) complexes (meso-1-PtLL': 2,6-F(2),3-OH; meso-2-PtLL': 2,6-F(2),4-OH; meso-3-PtLL': 2,6-Cl(2),3-OH; meso-4-PtLL': 2,6-Cl(2),4-OH; L = OH(2), L' = OSO(3) or L,L' = Cl(2)) were designed with the aim to get drugs comprising both cytotoxic and testosterone level lowering potencies. It is assumed that such compounds are more efficient than the established endocrine therapeutic measures and can affect the development of hormone refractory prostate cancer (PC). With exception of meso-3-PtLL' all Pt-complexes and the comparison compound cisplatin significantly reduced the testosterone level in experiments on male rats. However, in the test on the Dunning R3327 PC of the rat only cisplatin and meso-4-PtLL' showed a significant anti-tumor activity at well-tolerated dose ranges. Meso-4-PtLL' also significantly extended the time to disease progression in comparison with orchiectomy in this tumor model. Interestingly, the relapsed tumor, too, responded to meso-4-PtLL' as demonstrated in a long-term study on orchiectomized rats bearing Dunning R3327 PC grafts. This effect cannot be ascribed to cytotoxic effects of meso-4-PtLL' because of its inactivity on the human LNCaP/FGC PC cell line. Therefore, the contribution of an additional mechanism to the anti-prostate cancer activity of meso-4-PtLL', presumably owing to its estrogenic potency, must be considered. This assumption was supported by test results with diethylstilbestrol (DES) (non-steroidal estrogen) on the Dunning R3327 PC of the rat relapsed after orchiectomy. This tumor model was strongly inhibited by DES. The possible mode of action of meso-4-PtLL' is thoroughly discussed.
Schertl
Sabine
S
Lehrstuhl für Pharmazeutische Chemie II, Institut für Pharmazie, Universität Regensburg, 93040 Regensburg, Germany.
Hartmann
Rolf W
RW
Batzl-Hartmann
Christine
C
Spruss
Thilo
T
Maucher
Anton
A
von Angerer
Erwin
E
Schiller
Claus D
CD
Schneider
Martin R
MR
Gust
Ronald
R
Schönenberger
Helmut
H
D000726:Androgen Antagonists / Q000494:pharmacology; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004054:Diethylstilbestrol / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005663:Furans / Q000494:pharmacology; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D009929:Organ Size / Q000187:drug effects; D009944:Organoplatinum Compounds / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011753:Pyrones / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013737:Testis / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D013739:Testosterone / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000097:blood
C488612:(1,2-bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine)platinum(II); C101587:(1,2-bis(2,6-difluoro-4-hydroxyphenyl)ethylenediamine)sulfatoplatinum(II); C458502:2,6-dimethyldifuro-8-pyrone; D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D005663:Furans; D009944:Organoplatinum Compounds; D011753:Pyrones; C078283:(1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum (II); D013739:Testosterone; D004054:Diethylstilbestrol